novo nordisk glp-1 receptor agonists weight management diabetes treatments In the original clinical trials looking at semaglutide (the in Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the after McKee's proposed FY2027 budget drops
Description
0.9% for oral semaglutide to active comparator, respectively), 100 mg of sitagliptin (PIONEER 3: baseline HbA1c 8.3%, 1.1% vs

NY Acad

2025;41(5):e70058
For providers, high out-of-pocket costs and inconsistent coverage create real barriers to delivering optimal care
